Allergy Therapeutics PLC

Allergy Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)22.00
  • Today's Change0.00 / 0.00%
  • Shares traded29.11k
  • 1 Year change-5.38%
  • Beta1.4937
Data delayed at least 20 minutes, as of May 13 2022 15:02 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Allergy Therapeutics plc is a United Kingdom-based commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines. Its segments include Central Europe, which include segments, such as Germany, Austria, Switzerland and the Netherlands; Southern Europe, which includes Italy, Spain and Other; the United Kingdom, and Rest of World. It sells both injectable and sublingual allergen-specific immunotherapies. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL and Peanut SCIT. Its vaccine candidates outside allergy include disease areas, including cancer, asthma, atopic dermatitis and psoriasis. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Venomil, VLP Peanut and ImmunoBON.

  • Revenue in GBP (TTM)79.00m
  • Net income in GBP-5.38m
  • Incorporated2004
  • Employees601.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Staffline Group Plc942.70m1.60m83.72m2.34k89.,553.100.6873-6.112.39-13.168.789.490.1697-1.71--1.250.2874--1.631.33103.30-36.08-8.19--
Open Orphan PLC35.47m-3.07m91.11m179.00--4.19--2.57-0.0038-0.00380.04970.03250.9216--6.12198,156.40-7.88-32.72-11.83-55.59-----8.55-34.481.26-10.940.1045--510.9719.85-88.03--10.27--
Arecor Therapeutics PLC1.16m-6.17m108.56m30.00--5.85--93.74-0.2796-0.27960.05030.66640.0919--0.7416---48.95---57.31-------532.73-----12.730.0123---31.79---124.13------
Manolete Partners PLC27.83m5.70m118.12m16.0021.023.0220.154.240.12840.12840.62480.89340.5325--4.531,739,500.0010.9116.0411.8718.2548.1964.0220.4829.87--18.180.170210.8848.9842.15-25.1530.62----
Mind Gym PLC49.06m1.32m120.13m276.0090.506.7147.822.450.01330.01330.49130.17891.66--6.79177,742.804.4815.526.8626.9586.3581.202.708.80--14.220.131918.89-18.389.49-103.93--50.93--
Eckoh PLC29.53m2.67m122.21m230.0041.264.7727.224.140.01020.01020.11260.08810.726526.212.44128,408.706.574.8811.738.7178.8879.659.056.501.5571.570.048258.96-8.116.31-10.917.593.616.27
Litigation Capital Management Ltd27.34m7.17m122.63m--16.872.3417.034.490.0610.0610.23520.44050.2789--1.96--7.317.738.098.8772.7460.2326.2219.67--6.180.3613---3.60130.8868.98---54.84--
Inspired PLC67.94m1.64m138.94m521.0087.962.0913.412.040.00160.00160.06720.06830.467982.332.60--
Allergy Therapeutics plc79.00m-5.38m141.68m601.00--2.58--1.79-0.0091-0.00910.1190.08540.82732.237.33131,439.30-5.641.01-6.811.3370.7574.38-6.810.92133.16-13.580.1530.007.8311.69-59.11--15.77--
Anexo Group PLC98.44m14.45m150.44m731.0010.451.266.861.530.1220.1220.83111.020.5909--0.6784134,669.008.6712.6412.0518.0577.7576.9314.6721.37--
Begbies Traynor Group plc98.61m146.00k181.37m895.001,036.842.1621.561.840.00110.00110.65780.54620.7502--12.42124,817.700.11110.9090.15741.1642.6042.780.14811.57--14.060.1367323.6518.9010.83-83.57-19.3420.616.40
Science Group PLC81.22m9.56m181.62m410.0018.432.7613.012.240.2170.2171.841.450.781--7.06198,087.809.195.3113.267.44----11.777.321.507.370.2029--10.2517.0935.8328.31-25.88--
Macfarlane Group PLC264.47m13.75m187.80m1.04k13.801.987.130.71010.08620.0791.660.60131.369.434.81254,783.207.076.2111.2510.9533.8332.175.204.420.889314.500.320627.2525.808.0341.1917.8413.2610.41
Pebble Group PLC115.10m7.35m189.22m461.0025.792.5415.581.640.04380.04380.68460.44541.056.594.57249,676.806.68-0.86339.10-1.2436.4734.236.38-0.8281.3224.580.0944--39.739.2180.07--37.91--
Tribal Group plc81.15m6.99m189.48m936.0027.964.0917.682.340.03220.03220.37750.22030.8928--7.0486,696.587.694.2414.358.5451.5350.698.624.32----0.047882.0311.23-2.109.99--35.35--
Keystone Law Group PLC69.62m6.65m201.72m63.0030.7110.6826.802.900.,105,012.0018.8214.5035.3426.7026.4326.629.558.26--96.170.055569.9626.5122.1953.6150.27-10.74--
Data as of May 13 2022. Currency figures normalised to Allergy Therapeutics PLC's reporting currency: UK Pound GBX

Institutional shareholders

32.81%Per cent of shares held by top holders
HolderShares% Held
JPMorgan Chase Bank, NA (Investment Management)as of 02 Mar 2022144.35m22.42%
River & Mercantile Asset Management LLPas of 08 Feb 202230.35m4.71%
Hargreaves Lansdown Stockbrokers Ltd.as of 02 Mar 20229.01m1.40%
Odey Asset Management LLPas of 02 Mar 20228.58m1.33%
Hargreaves Lansdown Asset Management Ltd.as of 02 Mar 20224.07m0.63%
Teviot Partners LLPas of 02 Mar 20223.89m0.60%
Santander Asset Management SA SGIICas of 02 Mar 20223.13m0.49%
Medical Strategy GmbHas of 31 Jan 20222.93m0.46%
Hauck & Aufh�user Privatbankiers AGas of 02 Mar 20222.50m0.39%
CRUX Asset Management Ltd.as of 30 Sep 20202.50m0.39%
More ▼
Data from 30 Apr 2021 - 05 May 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.